

# Respiratory Drive, Dyspnea, and Silent Hypoxemia: A Physiological Review in the Context of COVID-19

Richard H Kallet, Richard D Branson, and Michael S Lipnick

## Introduction

### Control of Breathing and Hypoxemic Cardiovascular Compensation

#### The Hypoxic Ventilatory Response

#### Cardiovascular Responses to Worsening Hypoxemia

#### Severe Hypoxemia and Cardiorespiratory Decompensation in COVID-19

#### Respiratory Drive in Response to Hypercapnia and Acidosis

#### Respiratory Drive Variability: Neurotransmitter and Genetic Considerations

#### Respiratory Drive in ARDS

#### Respiratory Drive and the Theory of Minimal Work

### Breathing Perception and Dyspnea

#### Definitions and Nuanced Distinctions

#### The Theory of Length-Tension Inappropriateness

#### Dyspnea as Neuromechanical Dissociation

#### Hypoxemic-Induced Dyspnea

#### Hypoxic Ventilatory Decline as Happy Hypoxia

#### Hypercapnia and Breathlessness

#### Dyspnea in the Laboratory Setting: Interplay Between Hypoxemia,

#### Hypercapnia, and Hypocapnia

#### Hypoxemia and Neuromechanical Dissociation

### Silent Hypoxemia and COVID-19: Overview and Case Reports

### Silent Hypoxemia and COVID-19: Case-Controlled Studies

### Non-Neurogenic Explanations for Silent Hypoxemia in COVID-19

#### Impact of COVID-19 Type L ARDS on Dyspnea

#### Natural Variations in Control of Breathing, Comorbidities, and Altered

#### Mental Status

#### Accuracy of Pulse Oximetry and Apparent Silent Hypoxemia

### Neurologic Injury During COVID-19 as a Potential Source of Altered

### Perception of Dyspnea

### Summary

Infection with SARS-CoV-2 in select individuals results in viral sepsis, pneumonia, and hypoxic respiratory failure, collectively known as COVID-19. In the early months of the pandemic, the combination of novel disease presentation, enormous surges of critically ill patients, and severity of illness lent to early observations and pronouncements regarding COVID-19 that could not be scientifically validated owing to crisis circumstances. One of these was a phenomenon referred to as “happy hypoxia.” Widely discussed in the lay press, it was thought to represent a novel and perplexing phenomenon: severe hypoxemia coupled with the absence of respiratory distress and dyspnea. Silent hypoxemia is the preferred term describing an apparent lack of distress in the presence of hypoxemia. However, the phenomenon is well known among respiratory physiologists as hypoxic ventilatory decline. Silent hypoxemia can be explained by physiologic

mechanisms governing the control of breathing, breathing perception, and cardiovascular compensation. This narrative review examines silent hypoxemia during COVID-19 as well as hypotheses that viral infection of the central and peripheral nervous system may be implicated. Moreover, the credulous embrace of happy hypoxia and the novel hypotheses proposed to explain it has exposed significant misunderstandings among clinicians regarding the physiologic mechanisms governing both the control of breathing and the modulation of breathing sensations. Therefore, a substantial focus of this paper is to provide an in-depth review of these topics. *Key words: ARDS; silent hypoxia; hypoxic ventilatory response; hypoxic ventilatory decline; dyspnea; COVID-19.* [Respir Care 2022;67(10):1343–1360. © 2022 Daedalus Enterprises]

## Introduction

*“When faced with doubtful situations, we are likely to jump to new and attractive conclusions, because of ease of recall. Ironically, it is in these circumstances that our clinical judgement is most often needed.”*

Dipit Sahu<sup>1</sup>

During the first year of the COVID-19 pandemic, reports emerged in the medical literature describing what many authors believed was a uniquely COVID-19-related phenomenon of silent, happy, or apathetic hypoxia.<sup>2-7</sup> Because hypoxia occurs at the tissue level, it is hypoxemia that is actually being described. To avoid confusion in this presentation, the term hypoxia will be used either in its correct connotation or when citing other sources directly.

The alleged uniqueness of silent hypoxemia, amid the confusion and apprehension of a terrifying pandemic, all but guaranteed its rapid dissemination across social and mainstream media platforms. By July 2020, there were only 4 relevant COVID-19 publications listed on PubMed (of which only 2 were research articles), whereas a Google search using the term “happy hypoxia” produced over 2 million results.<sup>1</sup> The trivializing descriptor happy has been replaced with the preferred term silent hypoxemia.<sup>8,9</sup>

Initial reports from China mentioned apparent silent hypoxemia only passing. <sup>10,11</sup> One noted that chest computed tomography findings of diffuse, severe lung injury were

associated with relatively mild clinical presentations in some patients without complaint of dyspnea or signs of respiratory distress.<sup>11</sup> The first published case report of silent hypoxemia described a man in his 60s who, despite presenting with cyanosis and a pulse oximetry saturation 66%, was calm and cooperative with barely audible breathing. However, with ambulation he exhibited pronounced tachypnea that quickly rose to 48 breaths/min.<sup>7</sup> Upon hospital admission, his chest radiograph revealed diffuse bilateral lung opacities.

Other case reports followed describing stable patients with silent hypoxemia, some rapidly developed cardiovascular instability resulting in sudden death, whereas others recovered rapidly.<sup>3,5,6,11-14</sup> As of this writing, only 2 relatively large case-control studies have been published.<sup>15,16</sup> Given the backdrop of overwhelmed hospitals, it is understandable that concern over silent hypoxemia quickly evolved from curious novelty into alarm disproportionate to its apparent prevalence.

When reading these reports, one immediately notices that, when discussed at all, the neurophysiology of silent hypoxemia focuses entirely on intriguing hypotheses regarding COVID-19-related neurologic dysfunction. Conspicuously absent was any acknowledgment of more than a half century’s worth of physiological research into respiratory drive and dyspnea.<sup>17-21</sup> A broader perspective would have tempered the credulous embrace of novel hypotheses.

Only 2 early reports referenced studies describing the effects of hypobaric hypoxemia on respiratory drive and dyspnea or provided even a cursory overview of various mechanisms underlying dyspnea.<sup>7,14</sup> In the 2 years that have passed since the onset of the COVID-19 pandemic, more literature has emerged examining the phenomenon of silent hypoxemia, placing it within the context of our established understanding of respiratory drive and dyspnea. The objective of this narrative review is to explore each of these topics as well as provide a critical analysis of early reports that animated the discussion surrounding silent hypoxemia.

## Control of Breathing and Hypoxemic Cardiovascular Compensation

*“There is no single mechanism that can be said to control ventilation. Many different mechanisms can be shown to*

---

Mr Kallet and Dr Lipnick are affiliated with Department of Anesthesia and Perioperative Care, University of California, San Francisco at San Francisco General Hospital, San Francisco, California. Mr Branson is affiliated with Department of Surgery, Trauma and Critical Care Division, University of Cincinnati, Cincinnati, Ohio.

Mr Kallet has received honoraria from ContinuED. Mr Branson discloses relationships with Engineered Medical Systems, Pfizer, Mallinckrodt, Ventec Life Systems, and Vyair. Mr Branson is Editor in Chief of RESPIRATORY CARE. Dr Lipnick has disclosed no conflicts of interest.

Correspondence: Richard Kallet MSc RRT FAARC, 2070 Fell Street #1, San Francisco, CA. 94117-1878. E-mail: richkallet@gmail.com.

DOI: 10.4187/respcare.10075

*be able to exert an influence on breathing under particular circumstances, although not all are in play at any one time."*

*J.F. Nunn*<sup>22</sup>

The enormous complexity in the neural control of breathing is beyond the scope of this paper. Only a cursory overview is provided here to facilitate the reader's understanding of the ventilatory response during acute respiratory failure in general and COVID-19 in particular. Neurons residing in the central nervous system that regulate breathing are widely dispersed in the cerebral cortex, the hypothalamus, and other structures of the limbic/paralimbic system as well as the pons, medulla, and spinal respiratory neurons.

Basic rhythmicity is controlled by the central respiratory pattern generator, a column of neurons extending from the pons to the medulla (Fig. 1).<sup>23</sup> It emanates in small regions of the ventrolateral medulla (pre-Bötzinger complex, lateral parafacial region, and post-inspiratory complex) with additional phase control shaped by structures in the pons (Kölliker-fuse nucleus, parabrachial complex).<sup>24</sup> Together, these neural circuits influence breathing patterns under both physiologic and pathophysiologic conditions.<sup>25</sup> Additional inputs to rhythmicity are generated in upper cervical inspiratory neurons (at the level of C-1 and C-2) that project into areas near the phrenic and intercostal motor neurons.<sup>25</sup>

In addition, breathing rhythmicity is altered by cognitive, sensory, and emotional factors (eg, stress, pain, fear, anxiety) through activation of the limbic/paralimbic system.<sup>26,27,28</sup> Volitional control of breathing (eg, talking, singing) is controlled by the motor cortex. Furthermore, emerging evidence suggests severe physical exertion directly enhances hyperpnea by stimulating mechanically and metabolically sensitive afferent nerve fibers in the skeletal muscles.<sup>29</sup> These in turn projecting up into the medullary respiratory centers.

Chemosensitive structures in the ventral surface of the medulla regulate ventilation based upon local  $P_{aCO_2}$  tension and its corresponding impact upon intracellular hydrogen ion concentration ( $[H^+]$ ). Additional afferent information arises from stimulation of peripheral chemoreceptors for  $P_{aCO_2}$  in the carotid bodies that in turn enhance and quicken the response time of medullary chemoreceptors.<sup>30</sup> Concomitant hypoxemia detected in the carotid bodies also increases the sensitivity of neighboring  $P_{aCO_2}$  chemoreceptors (Fig. 2).<sup>31</sup>

Other vagal afferent stimuli that modify breathing (through integration of proprioceptive information) include muscle spindle fibers, tendon organ receptors, and joint receptors in the chest wall<sup>32,33</sup> as well as slow-adapting stretch receptors and irritant C-fibers in the airways and lung parenchyma (Fig. 2).<sup>29,34,35,36,37</sup>

Furthermore, acute lung injury results in the expression of pro-inflammatory cytokines in the brain stem that in turn induces tachypnea, even in the absence of chemosensitive and other afferent input.<sup>38</sup> And although arterial baroreceptors in

the carotid sinus and aortic arch primarily are involved in circulatory regulation, they also respond to hypotension by inducing hyperventilation.<sup>22</sup>

### The Hypoxic Ventilatory Response

*"Humans have been dealing with hypoxia in many different ways across evolution, both as breath-hold divers and as Indigenous permanent inhabitants of moderate to high altitude regions . . . proving that humans can thrive even in conditions of hypoxia."*

*Eric Mulder*<sup>39</sup>

Hypoxemia stimulates chemoreceptors in the carotid bodies that in turn modulate respiratory drive in a nonlinear fashion. The response is directly stimulated by decreased  $P_{aO_2}$  tension or hypotension ("stagnant hypoxia"), not by  $S_{aO_2}$ .<sup>40</sup> And in contrast to the stimulatory effects of acute hypercapnia on central respiratory drive, brain stem hypoxia exerts a directly depressant effect.<sup>22</sup>

The ventilatory threshold to hypoxemia occurs when  $P_{aO_2}$  sensed in the carotid bodies is  $\leq 60$  mm Hg.<sup>40-42</sup> The responses to acute hypoxemia (referred to as hypoxic ventilatory response) include tachypnea, hyperventilation, tachycardia, and elevated cardiac output, all of which rise proportionally as the severity of hypoxemia increases from mild to profound.<sup>42-45</sup>

Furthermore, the magnitude of the hypoxic ventilatory response is mediated by the corresponding  $P_{aCO_2}$ . When hypoxemia is induced in normal subjects, reducing  $P_{ETCO_2}$  tension to  $< 29$  mm Hg prevents the hypoxic ventilatory response even when  $S_{pO_2}$  is  $\leq 70\%$ . In contrast, the hypoxic ventilatory response is induced systematically when  $P_{ETCO_2}$  is  $\geq 34$  mm Hg.<sup>46</sup> That  $P_{ETCO_2}$  is normally  $\leq 5$  mm Hg below arterial values suggests that corresponding  $P_{aCO_2}$  levels of  $\sim 35$  and  $\sim 40$  mm Hg, respectively, either suppress or facilitate the hypoxic ventilatory response. Historically, acute acclimatization hypoxic drive becomes the primary driver of ventilation only at an altitude of  $\sim 13,000$  ft when  $P_{aO_2}$  reaches  $\sim 45$  mm Hg. Initial compensatory hyperventilation is mild, resulting in a  $P_{aCO_2}$   $\sim 35$ – $38$  mm Hg. Over time  $P_{aCO_2}$  stabilizes at  $\sim 30$  mm Hg, causing  $P_{aO_2}$  to stabilize at  $\sim 55$  mm Hg.<sup>22</sup> A more recent study in experienced mountaineers produced similar data (pH  $7.44 \pm 0.04$ ,  $P_{aCO_2}$   $35 \pm 5$  mm Hg,  $P_{aO_2}$   $47 \pm 8$  mm Hg,  $S_{aO_2}$   $83 \pm 5\%$ ) without discernable alterations in breathing frequency, heart rate, and blood pressure.<sup>47</sup>

### Cardiovascular Responses to Worsening Hypoxemia

Worsening hypoxemia proportionally increases the cardiovascular response. During mild hypoxemia ( $P_{aO_2}$  50–60 mm Hg,  $S_{aO_2}$  85–90%), both young and older adults as well as those with cardiovascular disease respond with increased




Fig. 1. Central nervous system illustrating the primary structures governing/modifying both the control of breathing and the perception of dyspnea. See text for descriptions. E-RDS = efferent-reafferent dissociation signaling (explaining dyspnea); KFN = Kölliker-fuse nucleus; NTS = nucleus tractus solitarius; PBC = parabrachial complex; P-BC= Pre-Bötzinger complex.




Fig. 2. Location of peripheral chemical and mechanical sensory receptors influencing the control of breathing and the sensation of dyspnea. Peripheral chemoreceptors located in the aortic arch and the carotid arteries are sensitive to both arterial CO<sub>2</sub> and oxygen tension. Chest wall mechanoreceptors located at the origins and insertions of the ribs provide information on displacement, whereas muscle tendons provide information regarding tension development, and muscle spindles provide integrated information. Pulmonary receptors include irritant receptors in the central and peripheral airways (C-fibers), J receptors, and stretch receptors located in the alveolar walls. From Reference 68.

heart rate and cardiac output (Fig. 3).<sup>43</sup> The ventilatory response appears mild until P<sub>aO<sub>2</sub></sub> reaches ~50 mm Hg, and the initial minute ventilation ( $\dot{V}_E$ ) response usually stabilizes at a new steady state within ~30 s.<sup>42</sup>

In moderate hypoxemia (P<sub>aO<sub>2</sub></sub> 40–50 mm Hg, S<sub>aO<sub>2</sub></sub> 75–80%), young adults continue to respond with increased heart rate, cardiac output, and increases in both pulmonary and systemic vascular resistance (ie, increased pulmonary arterial and systemic arterial blood pressure). In contrast, both aged adults and those with cardiovascular disease exhibit a less intense cardiovascular response. Consequently, metabolic acidosis may become apparent, and the risk of cardiovascular failure increases substantially.<sup>43</sup>

When hypoxemia is severe (P<sub>aO<sub>2</sub></sub> 30–40 mm Hg, S<sub>aO<sub>2</sub></sub> 50–75%), young healthy adults respond with substantially increased tachycardia and cardiac output, with acidemia becoming a prominent feature. Acidemia worsens even further in aged adults and those with limited cardiovascular compensatory reserves. Under these conditions, the risk of end-organ damage, acute cardiac injury, and cardiovascular collapse increases substantially.<sup>43</sup> Profound hypoxemia (P<sub>aO<sub>2</sub></sub> < 30 mm Hg, S<sub>aO<sub>2</sub></sub> < 50%) occurring clinically portends precipitous cardiovascular collapse that typically results in loss of consciousness, bradycardia, and shock.<sup>43</sup>

### Severe Hypoxemia and Cardiorespiratory Decompensation in COVID-19

During the early months of the pandemic, incidences of happy hypoxia coinciding with sudden, catastrophic




Fig. 3. Cardiovascular compensatory and decompensatory responses to increasing severity of hypoxemia comparing young/healthy subjects to both elderly subjects and those with cardiovascular disease. HR = heart rate; CO = cardiac output; PVR = pulmonary vascular resistance; SVR = systemic vascular resistance. From Reference 43, with permission.

hemodynamic collapse only amplified concerns regarding silent hypoxemia. That these concerns lead to mistaken comparisons with acute high-altitude hypoxic exposure obliges further examination of this issue, as both phenomena have a partial basis in physiology.

As described above, the normal response to an acute change in altitude and hypoxic hypoxia includes both hyperventilation and a hyperdynamic cardiac response. Here we refer to a rapid change as might occur in an unpressurized aircraft or even running the Pikes Peak marathon (ascent to ~14,200 ft) compared to acclimatization of individuals at high altitudes over prolonged periods of time.

The acute cardiorespiratory response preserves oxygen delivery coincident with the degree of hypoxemia. The simultaneous increase in  $\dot{V}_E$  reduces  $P_{aCO_2}$  and increases pH, both increasing alveolar oxygen based on the alveolar air equation, causing a leftward shift in the oxyhemoglobin disassociation (higher  $S_{aO_2}$  for a given  $P_{aO_2}$ ).<sup>14,22</sup>

In normal subjects at high altitude with normal lung mechanics, hyperventilation often manifests itself as a reduced breathing frequency and large tidal volume ( $V_T > 1.0$  L). This response is far different than that of a patient with viral pneumonia and reduced respiratory system compliance ( $C_{RS}$ ). In fact, hypoxemia is tolerated well by most individuals, yet the combination of hypoxemia and cardiovascular collapse (signifying loss of compensation) results in ischemia and anoxic injury. However, when cardiac output is normal or elevated, hypoxia loses its ability to wreck the machinery.

In contrast, when hypoxemia occurs in older patients and those with cardiovascular disease, hemodynamic and pulmonary compensation is limited. This is the basis for observations that patients with COVID-19 appeared to be “happy hypoxics” just prior to catastrophic collapse.<sup>48,49</sup> Thus, any preexisting disease that limits cardiac output hinders compensation. As underlying disease progresses and hypoxemia worsens, acidemia ensues, leading to cardiac failure and death.<sup>50,51</sup>

Sudden deterioration in both oxygen saturation and cardiovascular compensation may occur rapidly when hypoxemia primarily results from intrapulmonary shunt.<sup>52</sup> The combination of increased intrapulmonary shunt and a fall in  $\dot{V}_E$  and cardiac output, coupled with an  $S_{aO_2}$ - $P_{aO_2}$  resting on the steep part of the oxygen hemoglobin disassociation curve, portends impending failure. A reduction in cardiac output worsens hypoxemia through a decrease in mixed venous oxygen. Acidosis causes a right shift in the oxyhemoglobin disassociation curve, thus defeating compensatory mechanisms. On the steep portion of the oxyhemoglobin disassociation curve, minor changes in  $P_{aO_2}$  result in substantial changes in  $S_{aO_2}$ . These tenuous relationships may explain the signs of rapid deterioration seen in subjects with COVID-19 (Table 1).

### Respiratory Drive in Response to Hypercapnia and Acidosis

Absence of a  $P_{aO_2}$  chemosensitive response until a threshold of ~60 mm Hg is reached reflects the fact that

Table 1. Physiologic Changes Associated With Loss of Cardiovascular Compensation During Hypoxemia

Characteristic	Signifier
Acidemia	↓pH, ↑plasma lactate
Tissue hypoxia	↓ Mixed venous oxygenation (measured by near-infrared spectroscopy)
Peripheral vascular failure	↑ Vasopressor requirements despite adequate fluid resuscitation Orthostatic mediated changes in body position (won't tolerate head-up or prone position)
Myocardial ischemia	Elevated troponin level
Cardiac instability	Arrhythmias ↑ Heart rate variability Electrocardiographic signs of ischemia Echocardiographic evidence of altered myocardia contractility

$P_{aCO_2}$  and  $[H^+]$  are the most potent ventilatory stimuli and thus are the most tightly controlled variables during ventilation.<sup>53</sup> This is partly explained by the fact that  $CO_2$  (possessing a higher solubility at a similar molecular weight) is ~20 times more diffusible across tissues than  $O_2$ .<sup>54</sup> Thus, alterations in metabolism/respiration are detected much more rapidly through  $CO_2$  chemosensory pathways.

The response to acidosis does not differ between respiratory and metabolic origins<sup>22</sup> and is detected by peripheral and central chemoreceptors.<sup>55</sup> During the initial response to severe metabolic acidosis, the peripheral chemoreceptors are more important. In addition, when  $P_{aCO_2}$  increases and/or pH decreases, the carotid body receptors also become increasingly sensitive to hypoxemia.

In addition, during normal respiratory cycles, peripheral  $CO_2$  chemoreceptor output varies synchronously with small  $P_{aCO_2}$  oscillations. They are more sensitive and respond faster than central receptors to sudden changes in  $P_{aCO_2}$  (eg, during exercise).<sup>22,30</sup> Peripheral and central  $CO_2$  chemoreceptors work in concert so that peripheral receptor stimulation amplifies the corresponding output of the central receptors.<sup>54</sup>

The relationship between  $P_{aCO_2}$  and respiratory drive is signified by  $\dot{V}_E$  response curves that are linear and steep (slope of 2 L/min per mm Hg) at a normal  $P_{aO_2}$ . This acuity in  $P_{aCO_2}$  control is observed in both the early stages of sleep and during mild-to-moderate exercise when  $P_{aCO_2}$ , respectively, increases or decreases by only 1–3 mm Hg.<sup>56,57</sup> The curves also become steeper in response to severe hypoxemia ( $P_{aO_2}$  ~40 mm Hg) or severe metabolic acidosis.<sup>22</sup>

**Respiratory Drive Variability: Neurotransmitter and Genetic Considerations**

The hypoxic ventilatory response varies considerably between individuals. Some react with substantial increases in breathing frequency and/or  $V_T$ , whereas others exhibit little response. The accompanying cardiovascular response to hypoxemia shows similar interindividual variability.

Such variability is thought by some to reflect central neurotransmitter production and release (or accumulation) over time.<sup>58</sup> During acute or chronic hypoxemia, the excitatory neurotransmitter glutamate increases ventilatory demand.<sup>59</sup> As glutamate levels rise, so too does its conversion to gamma aminobutyric acid, a neurotransmitter that depresses ventilation. The biphasic ventilatory response to acute hypoxemia (described below) likely signifies the interplay of these neurotransmitters and perhaps reflects interindividual genetic differences in their expression.

Genetic variation in respiratory drive is suspected to account for interindividual differences found among diverse high-altitude populations around the world. Potentially over 1,000 genes might be involved in the adaptation to chronic hypoxemia.<sup>60</sup> Suspected genetic differences may account for the ~1–33% of various high-altitude populations who reportedly suffer from chronic mountain sickness (Monge disease), which breathlessness is a common symptom.<sup>60</sup>

In contrast, hypercapnia increases respiratory drive primarily through the excitatory effects of acetylcholine, the primary neurotransmitter governing basic rhythmicity.<sup>59</sup> There is emerging evidence possibly linking both sudden infant death syndrome and congenital central hypoventilation syndrome to mutations in the “ret” proto-oncogene responsible for prenatal neuronal development of  $CO_2$  chemosensitive pathways in the brain.<sup>59</sup>

**Respiratory Drive in ARDS**

The majority of patients with COVID-19-associated acute respiratory failure has or eventually develops ARDS.<sup>61</sup> Elevated respiratory drive in ARDS is multifactorial, and it is impossible to gauge the specific contributions of any one sensory input. Common characteristics associated with ARDS include rapid shallow breathing and vigorous inspiratory effort.<sup>62-64</sup> As described below, these pathologic alterations increase respiratory drive and contribute to the

sensation of dyspnea and breathlessness (as described below).

Lung inflammation also contributes to respiratory drive and altered breathing pattern. Both hydrostatic and altered permeability pulmonary edema, as well as endogenous substances (eg, histamine and prostaglandins), stimulate alveolar juxtapulmonary capillary receptors (J receptors). Stimulation of these irritant J receptors is associated with falling lung compliance that induces rapid shallow breathing.<sup>35,65,66</sup>

Stimulation of slow-adapting alveolar mechanoreceptors induces the Hering-Breuer deflation reflex, causing tachypnea and increased inspiratory force. These mechanoreceptors typically respond to sudden pronounced lung deflation, wherein the response intensity is proportional to the severity of lung collapse.<sup>37</sup> Although typically associated with pneumothorax, the deflationary reflex *theoretically might* enhance respiratory drive during an acute loss of functional residual capacity from congestive/compressive atelectasis (eg, fulminant ARDS).

Decreased  $C_{RS}$  with rising  $\dot{V}_E$  requirements in ARDS increases respiratory drive and work of breathing.<sup>67,68</sup> As an example, when  $C_{RS}$  is markedly reduced in ARDS, spontaneous rapid shallow breathing patterns are strongly associated with respiratory drive, peak inspiratory effort, and the magnitude of  $\dot{V}_E$  deficit (ie, the difference between what subjects can generate on their own during unassisted breathing vs what they can achieve during assisted mechanical ventilation).<sup>68</sup> In this particular study, a large  $\dot{V}_E$  deficit ( $\sim 3.5$ – $6.0$  L/min) likely reflected the additional effects of acute hypercapnia. This exemplifies what others have described in ARDS: the disparity between neural demand and respiratory muscle capacity (under loaded conditions) in the context of increased metabolic demand (metabolic hyperbola).<sup>69</sup>

### Respiratory Drive and the Theory of Minimal Work

Although rapid shallow breathing in ARDS may reflect input from afferent lung receptors, the pattern is consistent with the theory of minimal work proposed by Otis.<sup>70</sup> The theory posits that the central respiratory pattern generator selects a  $V_T$  and rate that minimizes the respiratory muscle power output needed to achieve sufficient  $\dot{V}_E$  to maintain gas exchange homeostasis. When  $C_{RS}$  is low, the most energy-efficient breathing pattern consists of a smaller  $V_T$  to minimize the elastic work of breathing (and, therefore, dyspnea), compensated for by an elevated breathing frequency.

The minimal work theory is supported by laboratory research in healthy humans demonstrating that respiratory muscle fatigue and muscle failure occur when the combined inspiratory force generated by all inspiratory muscles during tidal ventilation exceeds 50–70% of their maximal force capacity.<sup>71</sup> In ARDS, respiratory muscle weakness

also is prevalent, as is increased elastic work of breathing and  $\dot{V}_E$  demand. Hence, rapid shallow breathing can be construed as an adaptive survival mechanism that likely minimizes the sensation of dyspnea.

### Breathing Perception and Dyspnea

It is generally accepted that respiratory drive and dyspnea are intertwined as they share the same afferent receptors and are processed by the same central neural pathways.<sup>72</sup> Therefore, any mechanism that increases or reduces respiratory drive most likely has a similar impact on the perception of effort and the generation or amelioration of dyspnea.

### Definitions and Nuanced Distinctions

Dyspnea is a general term describing difficulty or unpleasantness in the act of breathing. Similar to pain, dyspnea possesses qualitatively distinct features of varying intensity processed by the same brain structures<sup>73</sup> so that both sensations likely produce similar degrees of suffering.

Dyspnea also is used in a specific manner to describe the perception that inspiratory effort is disproportionately greater than (out of balance with) the corresponding degree of simultaneous chest expansion.<sup>74</sup> Likewise, breathlessness specifically denotes an awareness of excessive ventilatory drive or an “unpleasant urge to breathe.”<sup>74</sup> This manifests either as an urge to breathe that cannot be met (eg, feeling winded) or situationally inappropriate (eg, elevated ventilation at rest). Although in its narrow usage dyspnea is associated with loaded breathing and breathlessness with chemosensory stimulation (hypoxic or hypercapnic), both sensations may be experienced simultaneously (eg, when severe metabolic acidosis, severe hypoxemia, and loaded breathing occur together in ARDS).<sup>75</sup>

Although confusing at times, dyspnea is most often used in its general sense as matter of convenience. The context in which the term is used often provides hints as to its intended specificity. For example, dyspnea is frequently substituted for breathlessness when the sensory effect of either hypoxemic or hypercapnic chemosensory stimulation is being described.

Other sources of dyspnea include J-receptor activation during pulmonary edema<sup>65</sup> and mechanoreceptor stimulation during acute lung volume loss.<sup>37</sup> Key to all these sensations is the *sense of alarm* generated by the awareness of an abnormal effort to breathe (the awareness of respiratory drive). Finally, the limbic/paralimbic system may cause breathlessness. This may occur indirectly with anxiety-induced hypocapnia that stimulates the amygdala or directly through hypercapnic-induced stimulation of the entire limbic/paralimbic system.<sup>76</sup>

Beyond these archetypical descriptors exists qualitatively distinct sensations commonly associated with specific cardiopulmonary diseases such as chest tightness (asthma), gasping (interstitial pulmonary fibrosis), burning (bronchitis), and suffocation (congestive heart failure). This varied and nuanced language often coincides with other descriptors that may change over the course of cardiopulmonary or neurologic disease as the mechanics of breathing and chemosensory input change.<sup>77</sup>

### The Theory of Length-Tension Inappropriateness

Dyspnea as mechanical difficulty in the act of breathing was conceived initially as an error-correcting proprioceptive mechanism, one that is generated by muscle spindle fibers during resistive, elastic, or threshold loading (ie, length-tension inappropriateness).<sup>75</sup> Abrupt loading increases muscle tension disproportionately greater than the corresponding, instantaneous degree of muscle shortening. This creates misalignment between parallel force-generating and stretch-stabilizing muscle fibers, which is sensed by afferently innervated connective tissue residing between these 2 fibers called muscle spindles. Muscle spindle activation stimulates a reflexive correction occurring at the medullary-pontine level. During the same or subsequent breaths, increasing inspiratory effort (muscle tension) corrects the error to achieve the targeted  $V_T$  (ie, chest displacement via muscle shortening), ensuring stable ventilation.

Because dyspnea denotes conscious awareness, critical thresholds of afferent stimuli associated with respiratory drive (ie, the summation of inputs from length-tension proprioceptors,  $CO_2$  and  $O_2$  chemoreceptors, and mechanical and irritant receptors) project up to higher brain centers (ie, thalamus, limbic/paralimbic, and sensory/motor cortices). This is achieved by stimulation of a diffusive web of regulatory neurons within the reticular formation (ie, medulla, pons, and upper cervical spinal cord) that mediates reflexive and other nonconscious vital functions (Fig. 1).

### Dyspnea as Neuromechanical Dissociation

Although the theory of length-tension inappropriateness was paradigmatic for studying dyspnea in the 1960s, its vagueness regarding the governing mechanism *once dyspnea is perceived* reflected the limited knowledge at that time. Approximately 40 years later, a new iteration of the theory described dyspnea as neuromechanical dissociation or efferent-reafferent-dissociation signaling,<sup>78-80</sup> whereby dyspnea constitutes *an unexpected event*.<sup>81</sup>

Disturbing respiratory sensations, as well as the response to them, are governed primarily by interactions between the somatosensory and motor cortices. This occurs through the mechanism of corollary discharge that describes the cross-communication between these 2 structures. Once aroused,

both the sensory and motor cortices take executive control over respiratory drive (eg, “I feel like I have to concentrate on my breathing”). Efferent impulses from the motor cortex are sent in parallel to both the medullary centers and the somatosensory cortex. The somatosensory cortex in turn interprets (compares) the strength of efferent impulses to the strength of integrated afferent impulses it receives simultaneously. Thus, the conception of dyspnea has evolved from length-tension inappropriateness to efferent-reafferent-dissociation signaling (Fig. 1).

### Hypoxemic-Induced Dyspnea

Healthy subjects exposed to hypoxemia appear unable to detect altered breathing sensations between  $S_{pO_2}$  80% versus 90%,<sup>82</sup> and hikers ascending to ~14,200 ft (eg, Pikes Peak, Colorado, estimated  $P_{aO_2}$  ~40 mm Hg) may or may not experience dyspnea.<sup>83</sup>

This marked variability in hypoxemia’s dyspnoenic potency was illustrated using experimental data on hypoxemia-induced dyspnea at rest. At the cusp of severe hypoxemia (ie,  $P_{aO_2}$  40 mm Hg,  $P_{aCO_2}$  40 mm Hg), an estimated 30% of individuals would not experience significant dyspnea.<sup>8</sup> Even during severe hypoxemia ( $S_{aO_2} < 70\%$ ), individual responses have ranged from profound dyspnea and panic to calmness and a sense of well-being.<sup>43</sup> Others reported that if subjects were allowed to set their own  $\dot{V}_E$  breathlessness was virtually undetectable at  $P_{aO_2}$  40–45 mm Hg.<sup>84</sup> And even when instructed to constrain their  $\dot{V}_E$  to resting levels, severe air hunger was not experienced by 50% of subjects.

### Hypoxic Ventilatory Decline as Happy Hypoxia

The *absence of distress* during hypoxemia is partly accounted for by hypoxic ventilatory decline. Just as there are mechanisms that stimulate the ventilatory response to hypoxemia, there also exist inhibitory mechanisms. Ventilatory response to hypoxemia also changes over time and may decline within as little as 15–20 min, becoming increasingly periodic despite worsening or persistent hypoxemia (Fig. 4).<sup>43</sup>

A clinically relevant example of hypoxic ventilatory decline was reported by Easton et al<sup>58</sup> describing a biphasic ventilatory response to sustained hypoxemia over ~30 min. Moderate hypoxemia ( $S_{aO_2}$  80%) under isocapnic conditions caused an immediate ~60% rise in  $\dot{V}_E$  (from 8 to ~13 L/min). However, within ~5 min  $\dot{V}_E$  declined to a plateau ~20% above baseline. This suggests that a relatively rapid inhibitory effect upon respiratory drive occurs and functions *independently* of  $P_{aCO_2}$ . This likely reflects the homeostatic interplay between excitatory-depressive neurotransmitters as the sudden, large release of glutamate also increases gamma aminobutyric acid






Fig. 4. Representation of hypoxic ventilatory response signified by a sudden, initial rise and minute ventilation ( $\dot{V}_E$ ) and subsequent cessation or reduction to a plateau somewhere above the initial baseline (ie, hypoxic ventilatory decline). The secondary rise over a period of weeks represents the process of acclimatization to living at higher altitudes (eg, 14,000 ft above sea level). Adapted from Reference 43.

levels, thus creating a biochemical brake that establishes a new, albeit higher equilibrium.

In passing, the actual sense of profound well-being is distinct from the mere absence of distress. The former initially was described in 1875 by Gaston Tissandier, the lone survivor of a tragic high-altitude ballooning experiment. At ~23,000 ft, he experienced an overall sense of “oppression,” quickly relieved by periodically breathing from a bag containing 60% O<sub>2</sub>. But at ~25,000 ft (estimated P<sub>aO<sub>2</sub></sub> < 20 mm Hg), he reported a “numbness of experience” with the “mind weakened little by little” in which he experienced “rising, inner joy” and “indifference” to the danger of which he was cognizant.<sup>74</sup> Similar reports regarding trekking accidents on Mount Everest (~29,000 ft) and similar high-altitude peaks have been attributed to hypoxia-induced “poor judgment.”<sup>85</sup>

Experiences of calm and well-being have been reproduced in hypobaric simulation studies when hypoxemia is accompanied by hyperventilation.<sup>44</sup> In one such simulation of 30,000 ft resulting in P<sub>aO<sub>2</sub></sub> 22–28 mm Hg and P<sub>aCO<sub>2</sub></sub> 16–31 mm Hg, the vast majority of subjects (89%) was alert and cooperative, with no signs of respiratory distress. However, if euphoria was experienced, it apparently was not salient enough to merit mentioning by the investigators.<sup>86</sup>

### Hypercapnia and Breathlessness

It bears repeating that unless P<sub>aO<sub>2</sub></sub> is ~45 mm Hg hypoxemia alone *often* does not induce dyspnea, particularly when P<sub>aCO<sub>2</sub></sub> is < 40 mm Hg.<sup>8,40</sup> A study examining how acute hypercapnia generates breathlessness in normal subjects found that by increasing P<sub>ETCO<sub>2</sub></sub> from 39–43 mm Hg only a slight sensation of breathlessness was experienced.<sup>87</sup> In contrast, breathlessness intensified rapidly as P<sub>ETCO<sub>2</sub></sub> rose to 45–48 mm Hg, becoming intolerable at ~50 mm Hg. In another

study, the threshold of severe breathlessness occurred at P<sub>ETCO<sub>2</sub></sub> ~10 mm Hg above baseline.<sup>88</sup> Given that P<sub>ETCO<sub>2</sub></sub> is normally ≤ 5 mm Hg < P<sub>aCO<sub>2</sub></sub>, it suggests that mild breathlessness is induced at a maximum P<sub>aCO<sub>2</sub></sub> ~48 mm Hg, increasing in intensity between 50–53 mm Hg and becoming intolerable at a maximum P<sub>aCO<sub>2</sub></sub> ~55 mm Hg.

### Dyspnea in the Laboratory Setting: Interplay Between Hypoxemia, Hypercapnia, and Hypocapnia

The stimulatory weakness of hypoxemia and its modulation by the corresponding P<sub>aCO<sub>2</sub></sub> have been elegantly illustrated in other laboratory studies of dyspnea. In one study, an acute drop in P<sub>aO<sub>2</sub></sub> from 96 to 47 mm Hg barely registered as breathlessness on intensity rating scales when P<sub>aCO<sub>2</sub></sub> was 35 ± 5 mm Hg.<sup>47</sup> Another found a 10 mm Hg decrement in P<sub>aCO<sub>2</sub></sub> (~30 mm Hg) essentially abolished hypoxemic-induced breathlessness.<sup>89</sup> Thus, at least modest-to-moderate degrees of hypocapnia suppress dyspnea as part of the hypoxic ventilatory response.

The intensity of breathlessness also has been compared using different inspired gas mixtures (ie, hyperoxic and hypoxic mixtures combined with hypercarbic and hypocarbic mixtures).<sup>74</sup> Breathlessness was most intense when breathing a hypercarbic-hypoxic gas mixture and was reduced slightly when breathing a hypercarbic-hyperoxic gas mixture. And in relevance to silent hypoxemia, only modest breathlessness was observed while breathing a hypoxic-hypocarbic gas mixture.

### Hypoxemia and Neuromechanical Dissociation

When considering hypoxemia as a source of dyspnea, it is noteworthy that a precipitous decline in S<sub>aO<sub>2</sub></sub> to 80%

increases peak inspiratory muscle pressure by  $\sim 8$  cm H<sub>2</sub>O (manifested by increased  $V_T$  rather than frequency).<sup>89</sup> This represents a very small fraction of normal inspiratory muscle pressure reserve ( $\geq 120$  cm H<sub>2</sub>O).<sup>71,90,91</sup>

Perception of dyspnea during mechanical loading is best expressed as the ratio of pressure generated during tidal breathing relative to inspiratory muscle pressure reserve ( $P_I/P_{I-max}$ ), with the intensity of dyspnea increasing linearly with the fractional increase in effort.<sup>92-94</sup> The perception of severe effort occurs when  $P_I/P_{I-max}$  is  $\geq 50\%$ .<sup>95</sup> Applying these proprioceptive findings to the early phase of COVID-19 (ie, when functional residual capacity,  $C_{RS}$ , and muscle strength are relatively well preserved) suggests the likelihood of dyspnea associated with hypoxemia-induced ventilatory demand is likely minor (see COVID-19 Type L ARDS below).

### Silent Hypoxemia and COVID-19: Overview and Case Reports

As described in the introduction, initial reports from China mentioned silent hypoxemia only in passing. The largest study to do so ( $\sim 1,100$  cases) reported shortness of breath in 205 subjects ( $\sim 19\%$ ), the majority of whom (68%) described it as mild.<sup>96</sup> Curiously, some interpreted these findings as reflecting the prevalence of silent hypoxemia.<sup>6,97</sup> Yet the veracity of these data is indeterminant. It was largely based upon evaluations done at hospital admission. Therefore, it likely missed hypoxemic subjects in whom dyspnea subsequently developed as pneumonia worsened. More importantly, the presence or absence of dyspnea was not correlated to concurrent assessments of oxygenation, ventilation, breathing pattern, or radiographic presentation.

A clearer perspective was provided by 6 studies published in 2020 ( $N \sim 1,700$  subjects). These reports recorded baseline symptoms and found dyspnea occurred frequently, ranging between 35–91% with an average incidence of 61%.<sup>98-103</sup> In a prospective study of 30 hospitalized subjects with mild COVID-19 (ie, not requiring ICU admission), 73% complained of dyspnea, all of whom had normal or heightened alveolar ventilation.<sup>104</sup>

We found 7 case reports/case series describing apparent silent hypoxemia in a total of 12 subjects. Arterial blood gas (ABG) data accompanied  $S_{pO_2}$  measurements in 8 subjects (Table 2). In 2 subjects,  $S_{pO_2}$  was  $\geq 85\%$  (mild hypoxemia),<sup>5,13</sup> and in 7  $S_{pO_2}$  was  $\leq 75\%$  (severe hypoxemia).<sup>7,14,105,106</sup> Among 3 subjects whose  $S_{pO_2}$  ranged from 60–66%, their corresponding  $P_{aO_2}$  was substantially  $>$  predicted (51–56 mm Hg).<sup>105</sup> Among 8 subjects with ABG data,  $P_{aCO_2}$  was reported in only 3, each of whom exhibited mild-to-moderate hyperventilation. Interestingly, in 2 other subjects with supposed silent hypoxemia, one was actually experiencing mild dyspnea and was tachypneic,<sup>12</sup> whereas

the other was never directly questioned about experiencing any breathing discomfort.<sup>5</sup>

### Silent Hypoxemia and COVID-19: Case-Controlled Studies

A retrospective case-control study ( $N = 213$ ) extracted data from electronic information systems at 2 Italian hospitals during the first wave of the pandemic.<sup>16</sup> Given the enormity of the crisis, the ability of clinicians to assess the quality and intensity of dyspnea understandably was limited, as was establishing baseline hypoxemia prior to initiating O<sub>2</sub> therapy. Data were absent in  $\sim 50\%$  of subjects. Approximately 32% of the remaining subjects were judged to have silent hypoxemia. Those without dyspnea were significantly less hypoxemic than dyspneic subjects ( $P_{aO_2}/F_{IO_2}$   $225 \pm 68$  mm Hg vs  $192 \pm 78$  mm Hg,  $P = .002$ ), and both cohorts exhibited mild hyperventilation ( $P_{aCO_2}$   $34 \pm 7$  mm Hg vs  $34 \pm 6$  mm Hg, respectively,  $P = .47$ ). When analyzed according to chest radiographic abnormalities, non-dyspneic subjects represented the majority of those ( $\sim 55\%$ ) with normal chest radiographs compared to  $\sim 25$ –35% with increasingly severe lung opacities.

Taken together, subjects with apparent silent hypoxemia had less severe lung injury and were observed either prior to developing ARDS or never developed the syndrome. The primary difficulty in interpreting this study is the absence of oxygenation differences between non-dyspneic and dyspneic cohorts in terms of  $P_{aO_2}$  ( $66 \pm 23$  mm Hg vs  $70 \pm 30$  mm Hg, respectively,  $P = .24$ ). This suggests that many non-dyspneic subjects either never reached the hypoxemic threshold for dyspnea or dyspnea was ameliorated by compensatory hypocapnia.

In another retrospective case-control study of 82 hypoxemic subjects, severity of dyspnea (assessed with the Borg CR10 scale) was compared between subjects with COVID-19 and subjects with chronic cardiopulmonary disease and/or community-acquired pneumonia.<sup>107</sup> Subjects with COVID-19 presented with minimal dyspnea and median (interquartile range [IQR]) Borg score 1 ( $\sim 0.5$ –2), translating into sensations described as just noticeable or weak. By contrast, subjects with chronic pulmonary disease tended toward pronounced dyspnea. Subjects with COVID-19 had a median  $P_{aO_2}$  64 (IQR 61–66) mm Hg and median  $P_{aCO_2}$  32 (IQR 31–36) mm Hg, respectively, with 71% having  $P_{aCO_2} < 35$  mm Hg. Thus again, apparent silent hypoxemia in subjects with COVID-19 could be explained by both the lack of sufficient hypoxemic stimulus and/or compensatory hyperventilation.

A prospective case-controlled study<sup>15</sup> represents the best evidence available to date because of 2 crucial design features: Enrollment required a baseline  $S_{pO_2} < 80\%$ , and variability in assessing dyspnea was minimized by mandating use of the American Thoracic Society definition (Table 3).<sup>108</sup> In

## COVID-19 AND SILENT HYPOXEMIA

Table 2. Case Reports, Brief Communication, and Observations From Studies Not Specifically Examining the Phenomenon of Silent Hypoxemia in COVID-19

Study/Category	Physical Presentation	ABG Findings	Radiographic Findings
Li, Ma <sup>11</sup> COVID-19 brief communication	General observations in some patients No complaint of dyspnea No signs of respiratory distress No ↑ in breathing frequency	NR	Multifocal bilateral opacities (ground glass pattern and consolidation)
Xie et al <sup>10</sup> COVID-19 review	General observation: “many patients had hypoxemia but without signs of respiratory distress, especially in elderly patients”	NR	NR
Ottestad <sup>7</sup> Case report	Male in 60s c/o “Somewhat SOB” Cyanotic Frequency: 36* breaths/min S <sub>pO<sub>2</sub></sub> : 66% on room air Heart rate: 104 beats/min BP: 120/80 mm Hg Calm, smiling Able to eat/ambulate	NR	Diffuse bilateral opacities
Wilkerson <sup>5</sup> Case report	72 y old male NAD, unlabored speech Patient not directly questioned about breathing discomfort S <sub>pO<sub>2</sub></sub> : 85–88% on room air Frequency: 14 breaths/min	Serum CO <sub>2</sub> : 25 mEq/L	Diffuse bilateral opacities
Widysanto <sup>12</sup> Case report	48 y old male Mild dyspnea S <sub>pO<sub>2</sub></sub> : 77% on room air Frequency: 30 breaths/min	pH: 7.50 P <sub>aCO<sub>2</sub></sub> : 29 mm Hg	Bilateral lung opacities (ground glass appearance)
Kobayashi <sup>13</sup> Case report	65 y old male Asymptomatic S <sub>pO<sub>2</sub></sub> : 86% on room air Other vital signs NR	NR	Mild, pneumonitis in bilateral lower lobes
Siswanto <sup>106</sup> Case report	60 y old male Uncontrolled DM Denial of dyspnea, unlabored breathing Room air S <sub>pO<sub>2</sub></sub> : 75%	NR	Bilateral pneumonia
Ratnayake <sup>105</sup> Case series	3 males, 1 female Ages: 53, 51, 43, 60 y Room air S <sub>pO<sub>2</sub></sub> : 60, 60, 66, 82% Unlabored speech, denial of dyspnea (rest or exertion)	Room air P <sub>aO<sub>2</sub></sub> : 56, 51, 54, 56 mm Hg P <sub>aCO<sub>2</sub></sub> : 26 mm Hg only reported in subject 2	Bilateral patchy opacities in all subjects at admission
Tobin <sup>14</sup> Case series	3 males: Ages: 58, 64, 74 y All with unlabored breathing All appeared comfortable O <sub>2</sub> therapy: NC, NRM, HFNC S <sub>pO<sub>2</sub></sub> : 68, 62, 76%	ABG P <sub>aO<sub>2</sub></sub> : 37, 36, 45 mm Hg S <sub>aO<sub>2</sub></sub> : 75, 69, 83% P <sub>aCO<sub>2</sub></sub> : 41, 34, 38 mm Hg	NR

\*Breathing frequency increased to 48 with ambulation.

ABG = arterial blood gas

NR = data not reported

S<sub>aO<sub>2</sub></sub> = arterial oxygen saturation

BP = arterial blood pressure

NAD = no apparent distress

DM = diabetes mellitus

NC = nasal cannula

NRM = non-rebreather mask

HFNC = high-flow nasal cannula

brief, only 5% of hypoxemic subjects with a median room air  $S_{pO_2}$  76% (IQR 60–79) presented with apparent silent hypoxemia, with 91% of these cases also presenting with tachypnea. These subjects had similar degrees of hypocapnia, with median  $P_{aCO_2}$  33 (IQR 30–37) mm Hg. These findings are consistent with those reported in healthy, severely hypoxemic research subjects experiencing minimal dyspnea when allowed to set their own  $P_{aCO_2}$ .<sup>47</sup>

Despite similar degrees of lung injury severity (based on chest computed tomography findings) and a similar  $P_{aO_2}/F_{IO_2}$  on the same  $F_{IO_2}$ , non-dyspneic subjects differed from dyspneic subjects in 3 respects: (1) They presented to the hospital 2 d earlier from symptom onset; (2) had a higher median room air  $S_{pO_2}$ , 76% (IQR 60–79) versus 70% (IQR 57–76), respectively, ( $P = .02$ ); and (3) had a lower median breathing frequency, 22 (IQR 20–26) versus 30 (IQR 26–36), respectively, ( $P < .001$ ).<sup>15</sup> Finally, neither age nor co-diagnosis of diabetes differed between cohorts, which might have explained the absence of dyspnea (as described below).

Finally, a smaller prospective case-control study examined subjects with non-severe COVID-19 for dyspnea, neurologic symptoms, and respiratory-related variables.<sup>109</sup> As assessed by structured interviews coupled with Borg scale evaluation, the incidence of dyspnea was 32%. Neither the presence of neurologic symptoms (eg, loss of smell or taste) nor respiratory frequency and ABG findings differed between dyspneic and eupneic subjects.

### Non-Neurogenic Explanations for Silent Hypoxemia in COVID-19

*“Whenever possible, substitute constructions out of known entities for inferences to unknown entities.”*

*Bertrand Russell*<sup>110</sup>

Several opinion pieces and reviews offered various perspectives on why some patients with COVID-19 appear to have silent hypoxemia.<sup>4,8,14,43,44,111</sup> To date, however, the only valid evidenced-based explanation for silent hypoxemia either in the absence of severe hypoxemia or when severe hypoxemia occurs with elevated  $P_{aCO_2}$  is that hypoxemia is a relatively weak stimulus both for respiratory drive and dyspnea.<sup>22,43,112,113</sup>

Confusion regarding apparent COVID-19-associated silent hypoxemia sometimes has involved puzzling, unorthodox definitions of hypoxemia. Some reports<sup>105,106</sup> mistakenly defined the hypoxemic threshold as  $P_{aO_2} < 80$  mm Hg (vs the experimentally established threshold of  $\leq 60$  mm Hg), thus attributing silent hypoxemia when it was not present.

Regarding ARDS (which the majority of hypoxemic patients with COVID-19 develops),<sup>114</sup> there is a tendency to interpret the coincidence of hypoxemia with dyspnea as

representing a cause-effect relationship. However, severe neuromechanical dissociation is the most likely source of dyspnea in ARDS. This occurs alongside less salient but key factors such as stimulation of afferent receptors in the pulmonary tissue as well as suprapontine inputs representing the psychological and emotional trauma associated with respiratory distress and critical illness.<sup>115,116</sup>

We suspect clinicians tend to associate low  $S_{pO_2}$  with dyspnea because of 3 factors. First, the almost reflexive focus on oxygenation when evaluating patients with respiratory disease. Second, the divergence between what physiologists versus clinicians consider to be severe hypoxemia (eg,  $S_{aO_2} \sim 75\%$  vs  $\sim 85\%$ , respectively). And third, the pervasive presence of  $S_{pO_2}$  visual stimuli in the clinical setting constantly reinforces the focus upon oxygenation. These factors likely divert attention away from less salient but more potent dyspnoegenic stimuli. In consequence, clinicians tend to overestimate the dyspnoegenic impact of hypoxemia. Given the stressful, chaotic circumstances during the pandemic, the expectation that hypoxemia and dyspnea coexist as a cause-effect relationship made its absence all the more conspicuous and perplexing. Thus, it was perceived as another manifestation of an unfamiliar and deeply frightening contagion.

### Impact of COVID-19 Type L ARDS on Dyspnea

A cogent explanation for apparent silent hypoxemia during COVID-19 involved the underlying pathophysiology during the early stages.<sup>4,43</sup> Gattinoni and colleagues described this as Type L (atypical ARDS) whereby coronavirus infection of the pulmonary vascular endothelium abolished compensatory hypoxemic pulmonary vasoconstriction. This caused profound ventilation-perfusion mismatching and severe hypoxemia, despite near-normal  $C_{RS}$ , functional residual capacity, and modest degrees of lung inflammation.<sup>117</sup> Type L ARDS also was hypothesized as causing self-inflicted lung injury. This presupposes both intact respiratory muscle strength and normal  $P_I/P_{I-MAX}$  proprioceptive relationships described earlier. Therefore, the ability to suppress or ameliorate dyspnea under Type L conditions only requires the ability to achieve modest hypocapnia at negligible increases in effort.

We calculated the corrected  $\dot{V}_E$ <sup>118</sup> from a large COVID-19 study ( $N = 267$ ) that published  $\dot{V}_E$  and corresponding  $P_{aCO_2}$  data.<sup>119</sup> Study subjects in the 25th and 50th quartiles had an initial corrected  $\dot{V}_E$  (ie, that needed to achieve  $P_{aCO_2}$  40 mm Hg)<sup>118</sup> that was  $\leq 7.7$  L/min and  $\leq 10.3$  L/min, respectively. Modestly higher  $\dot{V}_E$  levels needed to achieve mild hypocapnia in a large number of these subjects would appear highly plausible under Type L conditions. Likewise, the corresponding respiratory muscle power output and central drive needed to achieve suppressive  $P_{aCO_2}$  (ie,  $35 \pm 5$  mm Hg)<sup>47</sup> would be negligible.

Table 3. Data from Garcia-Grimshaw et al Prospective Case-Control Study Comparing Dyspneic Versus Non-Dyspneic Subjects With COVID-19 Presenting With Hypoxemia

Design	Variables	Dyspneic Cohort	Non-Dyspneic Cohort
Definitions	<i>N</i> = 470	<i>n</i> = 447 (95%)	<i>n</i> = 23 (5%)
Dyspnea: ATS criteria	Initial study day**	8 (6–12)	6 (2–8)‡
Silent hypoxemia: absence of dyspnea when $S_{pO_2} < 80\%$ on room air	Room air $S_{pO_2}$	70 (57–76)	76 (60–79)‡
	Frequency, breaths/min	30 (26–36)	22 (20–26)‡
	% Tachypnea, > 20		
	Heart rate, beats/min	94	91
	Systolic BP, mm Hg	104 (91–116)	102 (85–117)
	Temperature, °C	125 (110–136)	126 (120–140)
	Arterial pH	37.0 (36.5–37.3)	37 (36.5–37.5)
	$P_{aCO_2}$ , mm Hg	7.44 (7.40–7.46)	7.44 (7.41–7.47)
	$P_{aO_2}$ , mm Hg	31 (28–35)	33 (30–37)
	$HCO_3^-$ , mmol/L	64 (53–77)	66 (49–78)
	$F_{IO_2}$	21.2 (18.8–23.5)	23.6 (20.6–25.8)
	$P_{aO_2}/F_{IO_2}$ , mm Hg	0.60 (0.40–0.60)	0.60 (0.40–0.60)
	Severe CT findings§	125 (97–173)	129 (82–197)
	Age, y	86.1	82.6
	Diabetes	55 (46–64)	52 (42–67)
	Anosmia/dysgeusia	33	39
	Headache	4.9	4.3
		35.1	56.5‡

Data are presented as *n* and median (interquartile range) or %.

\*Days from symptom onset to presentation in the emergency department.

†Data presented as median (25–75% interquartile range).

‡Results reported as statistically significant.

§Presence of consolidation/ground glass opacities > 50% of lung fields as assessed by semi-quantitative chest computed tomography.

ATS = American Thoracic Society

BP = blood pressure

CT = computed tomography

### Natural Variations in Control of Breathing, Comorbidities, and Altered Mental Status

Others have advanced equally compelling explanations for apparent silent hypoxemia not requiring coronavirus infection of the peripheral and/or central and nervous systems.<sup>8,43</sup> First, there exists a 10-fold difference in respiratory drive in how individuals respond to hypoxemia and hypercapnia, supported by physiologic research into natural variations in respiratory drive among high-altitude populations. Second, both older individuals and those with diabetes have blunted ventilatory response to chemoreceptor stimulation.<sup>49,120</sup> Studies of older subjects (64–73 y old) found respiratory drive responses to both hypoxemia and hypercapnia are reduced by 40–50% compared to young adults (22–30 y old).<sup>48,49</sup>

This information is particularly important in assessing silent hypoxemia during the first wave of COVID-19, when hospitalized subjects with COVID-19 largely were older and/or had diabetes as a comorbidity. In one study, 44% of subjects was ≥ 65 y old, and 37% had diabetes,<sup>98</sup> whereas in other studies 23–54% of subjects was ≥ 70 y old, and 17–28% had diabetes.<sup>121,122</sup> Hence, a sizable percentage of hospitalized subjects with COVID-19 likely had blunted

hypoxemic ventilatory response at baseline. The tendency toward blunted hypoxic drive during the first wave of COVID-19 far exceeded the actual incidence of apparent silent hypoxemia (5%) reported in the largest, best-controlled prospective study specifically focused on this phenomenon.<sup>15</sup>

Finally, acutely ill hypoxemic patients often have altered mental status that can mask symptoms.<sup>8</sup> This makes the veracity of diagnosing silent hypoxemia all the more problematic, particularly so when trying to evaluate and triage patients in the chaotic environment that was the early months of the pandemic. In such circumstances, the careful, time-consuming evaluation required to accurately assess dyspnea was at best impractical if not impossible.<sup>115</sup>

### Accuracy of Pulse Oximetry and Apparent Silent Hypoxemia

Within the construct of diagnosing hypoxemia, a return to the principles that govern the relationship of  $P_{aO_2}$  and  $S_{aO_2}$  as well as factors impacting the accuracy of pulse oximetry is in order. Pulse oximeters are ubiquitous in all health care facilities and perhaps deceptively simple. Our intent here is not to

cover all the factors that impact oximetry accuracy but rather to highlight those seen with COVID-19 that might suggest a lower  $S_{pO_2}$  than is actually present.<sup>123</sup>

The  $P_{aO_2}$ - $S_{aO_2}$  relationship is described by the sigmoid shape of the oxyhemoglobin disassociation curve.<sup>124</sup> Under normal physiology,  $S_{aO_2}$  90% is typically associated with  $P_{aO_2}$  60 mm Hg. Over decades, the mnemonic “30–60, 60–90, 40–75” has aided clinicians as a rule of thumb for remembering the  $P_{aO_2}$ - $S_{aO_2}$  relationship. With alterations in physiology, associated changes in temperature,  $P_{aCO_2}$ , 2–3 diphosphoglycerate, and pH alter the normal  $P_{aO_2}$ - $S_{aO_2}$  relationship.

COVID-19 results in ARDS and profound hypoxemia but also often results in viral sepsis. With viral sepsis, both body temperature changes and hypotension (impacting signal quality) conspire to alter bedside oximeter accuracy. With respect to oxygenation status, a change in body temperature from 37°C to 40°C at a constant pH and  $P_{aCO_2}$  will cause  $S_{aO_2}$  to fall from 91% to 86%, a decrease of 5% for the same  $P_{aO_2}$ .<sup>14</sup> At a lower  $P_{aO_2}$ , on the steeper portion of the oxyhemoglobin disassociation curve, the magnitude of change is greater. Clinically, this means a lower measured  $S_{pO_2}$  displayed by the oximeter for a  $P_{aO_2}$  value that does not meet the definition of hypoxemia or the suggested severity of hypoxemia. Clinically this is important in the discussion of silent hypoxemia, as carotid body chemoreceptors are sensitive only to  $P_{aO_2}$ , not  $S_{pO_2}$ .<sup>14</sup>

Pulse oximetry accuracy has been the focus of many publications and a major driver in this competitive market. However, the accuracy of pulse oximetry in critically ill mechanically ventilated patients is only  $\pm 4\%$ .<sup>125,126</sup> These inaccuracies may be further compounded by the presence of hypotension and a consequent poor signal quality.<sup>127</sup>

Sjoding et al<sup>128</sup> brought renewed attention to a well-known issue that oximetry accuracy is negatively impacted by skin pigment. Both the initial calibration of oximeters and the principle of operation (light through a tissue bed to a detector) account for greater inaccuracy. Jubran and Tobin<sup>129</sup> described this effect back in 1990, to far less fanfare but important clinical impact. They found that  $S_{pO_2}$  95% was required to assure  $P_{aO_2} > 60$  mm Hg in subjects with dark pigmentation. In one subject,  $S_{pO_2}$  90% was associated with  $P_{aO_2}$  49 mm Hg. Bickler and colleagues<sup>130,131</sup> also detailed the impact of skin pigment on accuracy of oximeters across a spectrum of  $S_{pO_2}$  values. Their studies predicted the findings by Sjoding et al nearly 20 years earlier, yet explanations for these results remain elusive.<sup>132</sup>

### Neurologic Injury During COVID-19 as a Potential Source of Altered Perception of Dyspnea

*“First Rule of Scientific Reasoning: We are to admit no more causes of natural things than such as are both true and sufficient to explain their appearance.”*

*Sir Isaac Newton<sup>133</sup>*

Several investigators have questioned whether respiratory drive is altered by SARS-CoV-2 central nervous system infection, thus presenting a potentially valid alternative explanation for silent hypoxemia.<sup>18,19,21,134</sup> All neurological infection hypotheses are based upon coronaviruses’ general ability to invade and live inside neural tissue (neurotropism).<sup>135</sup> SARS-CoV-2 has been observed to infect the brains of both animals and patients, with infection of the medullary cardiorespiratory centers found to be particularly severe in one study.<sup>134</sup>

Alternatively, Tobin and colleagues<sup>14</sup> suggested SARS-CoV-2 may infect the carotid bodies via endothelial angiotensin-converting enzyme 2 (ACE-2) receptors, thus blunting the ability of peripheral chemoreceptors to detect hypoxemia. Others have speculated that potential blunting of afferent stimuli might occur centrally in medullary structures receiving afferent signals from the carotid bodies (ie, via the nucleus tractus solitarius) (Fig. 1).<sup>18,21</sup> In contrast, Gattinoni and colleagues<sup>136</sup> proposed that SARS-CoV-2 infection of the carotid bodies might actually *magnify* hypoxic chemosensitivity, thus leading to patient self-inflicted lung injury.

Because ACE-2 receptors also are expressed in nasal mucosa, SARS-CoV-2 may enter the brain by infecting the olfactory bulb.<sup>134</sup> This route of infection was demonstrated with transnasal inoculation in animal models using various coronaviruses.<sup>137,138</sup> That anosmia and dysgeusia (loss of smell and taste) are often associated with COVID-19<sup>139</sup> provides circumstantial support for neuroinvasive hypotheses. However, as others<sup>109</sup> have observed, neither anosmia nor dysgeusia distinguishes subjects with COVID-19 based upon the presence or absence of dyspnea.

Mechanistically speaking, the most cogent explanation for silent hypoxemia among these hypotheses involves SARS-CoV-2 infection of the limbic system that governs emotions, particularly the amygdala, which plays a prominent role in generating fear and anxiety.<sup>140</sup> Ultimately, the validity of this hypothesis is predicated upon uncovering evidence that SARS-CoV-2 infection of the amygdala (or other structures in the limbic system) actually exerts a depressive effect on generating stressful emotions. To our knowledge no such direct evidence exists.

Most pertinent is that histopathological evidence supporting a linkage between SARS-CoV-2 central nervous system infection and silent hypoxemia is circumstantial at best and not particularly convincing. A postmortem histopathologic study of 20 subjects with COVID-19 tracing the route of brain infection found only a minority of subjects had definitive findings attributable to COVID-19.<sup>141</sup> Only 20% of subjects had SARS-CoV-2 RNA detected in at least one area of the brain, with only the olfactory bulb testing positive in more than one subject. In contrast, SARS-CoV-2 RNA was found in the amygdala or the medulla in a single

subject (5% incidence). Another histopathologic study of 20 subjects with COVID-19 focused exclusively on infection of both the olfactory bulb and the amygdala found substantially greater viral transcriptional changes in the olfactory bulb versus the amygdala.<sup>142</sup>

Although neurological infection hypotheses of silent hypoxemia are intriguing, and cannot be summarily dismissed, they are merely speculative and stand in stark contrast to a preponderance of established scientific evidence concluding that dyspnea is largely absent unless hypoxemia is severe.<sup>143,144</sup>

### Summary

Silent hypoxemia is a well-described phenomenon that predates COVID-19 and can be explained by known human physiologic responses to hypoxemia as well as the nature of dyspnea. Whether this phenomenon is more common in COVID-19 has yet to be determined. But based upon the evidence accrued thus far, it appears unlikely. However, the reason it is being observed mostly can be explained.

The most important findings of this review of silent hypoxemia are that respiratory drive is not depressed in COVID-19, and the absence of dyspnea is largely explained by compensatory hyperventilation. Quite often the degree of hypoxemia documented in reports was insufficient to provoke dyspnea. Among subjects in well-designed prospective studies of silent hypoxemia, the actual incidence was low. In addition, current evidence supporting coronavirus infection of the central nervous system as a source of silent hypoxemia is indirect and circumstantial. This is in stark contrast to decades of physiologic research on hypoxemia, respiratory drive, and dyspnea.

Nonetheless, the term happy hypoxemia should be retired from the lexicon, as despite patients with seemingly low  $S_{pO_2}$  and no overt signs of respiratory distress they are unlikely to have come to the hospital with viral pneumonia and remain happy. Understanding the underlying physiologic principles that govern these relationships is critical for adequate assessment of patients with hypoxemia and for critical care practice in general.

### REFERENCES

1. Sahu D, Agrawal T. Is it the COVID-19 happy hypoxia syndrome or the COVID-19 infodemic syndrome? *Diabetes Metab Syndr* 2020;14(5):1399.
2. Couzin-Frankel J. The mystery of the pandemic's "happy hypoxia." *Science* 2020;368(6490):455-456.
3. Garg RK, Uniyal R, Pandey S. Silent hypoxemia in COVID-19: dangerous, if gone undetected. *Neurol India* 2020;68(5):1261-1262.
4. Sheikh S, Baig MA. Silent hypoxia in COVID-19: what is old is new again!. *J Coll Physicians Surg Pak* 2020;30(6):70-71.
5. Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: a harbinger of clinical deterioration in patients with COVID-19. *Am J Emerg Med* 2020;38(10):2243.e2245-2243.e2246.

6. Machado-Curbelo C. Silent or "Happy" hypoxemia: an urgent dilemma for COVID-19 patient care. *MEDICC Rev* 2020;22(4):85-86.
7. Ottestad W, Seim M, Maehlen JO. COVID-19 with silent hypoxemia. *Tidsskr nor Laegeforen* 2020;140(7).
8. Simonson TS, Baker TL, Banzett RB, Bishop T, Dempsey JA, Feldman JL, et al. Silent hypoxemia in COVID-19 patients. *J Physiol* 2021;599(4):1057-1065.
9. Swenson KE, Ruoss SJ, Swenson ER. The pathophysiology and dangers of silent hypoxemia in COVID-19 lung injury. *Ann Am Thorac Soc* 2021.
10. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. *Intensive Care Med* 2020;46(5):837-840.
11. Li X, Ma X. Acute respiratory failure in COVID-19: is it "typical" ARDS? *Crit Care* 2020;24(1):198.
12. Widyanto A, Wahyuni TD, Simanjuntak LH, Sunarso S, Siahaan SS, Haryanto H, et al. Happy hypoxia in critical COVID-19 patient: a case report in Tangerang. *Physiol Rep* 2020;8(20):e14619.
13. Kobayashi K, Takaoka H, Hirano T, Inoue T. Dilemma of countering happy hypoxemia COVID-19 patients. *BMJ Case Rep* 2021;14(2):e241588.
14. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. *Am J Respir Crit Care Med* 2020;202(3):356-360.
15. Garcia-Grimshaw M, Flores-Silva FD, Chiquete E, Cantu-Brito C, Michel-Chavez A, Viguera-Hernandez AP, et al. Characteristics and predictors for silent hypoxemia in a cohort of hospitalized COVID-19 patients. *Auton Neurosci* 2021;235:102855.
16. Busana M, Gasperetti A, Giosa L, Forleo GB, Schiavone M, Mitacchione G, et al. Prevalence and outcome of silent hypoxemia in COVID-19. *Minerva Anestesiol* 2021;87(3):325-333.
17. Machado-Curbelo C. Severe COVID-19 Cases: is respiratory distress partially explained by central nervous system involvement? *MEDICC Rev* 2020;22(2):38-39.
18. Gonzalez-Duarte A, Norcliffe-Kaufmann L. Is "happy hypoxia" in COVID-19 a disorder of autonomic interoception? A hypothesis. *Clin Auton Res* 2020;30(4):331-333.
19. Nouri-Vaskeh M, Sharifi A, Khalili N, Zand R, Sharifi A. Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: possible neurological mechanism. *Clin Neurol Neurosurg* 2020;198:106217.
20. Coen M, Kaiser C, Naimi R, Uginet M, Hentsch L, Serratrice J, et al. Beyond silent hypoxemia: does COVID-19 can blunt pain perception? Comment on "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID 19 patients." *J Med Virol* 2021;93(4):1915-1916.
21. Anoop UR, Verma K. Happy hypoxemia in COVID-19 - a neural hypothesis. *ACS Chemical Neuroscience* 2020.
22. Nunn J. Control of breathing. *Applied respiratory physiology*. London: Butterworths; 1977: 26.
23. Dutschmann M, Dick TE. Pontine mechanisms of respiratory control. *Compr Physiol* 2012;2(4):2443-2469.
24. Jensen VN, Alilain WJ, Crone SA. Role of propriospinal neurons in control of respiratory muscles and recovery of breathing following injury. *Front Syst Neurosci* 2019;13(84):84.
25. Ikeda K, Kawakami K, Onimaru H, Okada Y, Yokota S, Koshiya N, et al. The respiratory control mechanisms in the brainstem and spinal cord: integrative views of the neuroanatomy and neurophysiology. *J Physiol Sci* 2017;67(1):45-62.
26. Evans KC, Dougherty DD, Schmid AM, Scannell E, McCallister A, Benson H, et al. Modulation of spontaneous breathing via limbic/paralimbic-bulbar circuitry: an event-related fMRI study. *Neuroimage* 2009;47(3):961-971.
27. Fukushi I, Yokota S, Okada Y. The role of the hypothalamus in modulation of respiration. *Respir Physiol Neurobiol* 2019;265:172-179.

28. Tipton MJ, Harper A, Paton JFR, Costello JT. The human ventilatory response to stress: rate or depth? *J Physiol* 2017;595(17):5729-5752.
29. Bruce RM, Jolley C, White MJ. Control of exercise hyperpnea: contributions from thin-fiber skeletal muscle afferents. *Exp Physiol* 2019;104(11):1605-1621.
30. Smith CA, Rodman JR, Chenuel BJ, Henderson KS, Dempsey JA. Response time and sensitivity of the ventilatory response to CO<sub>2</sub> in unanesthetized intact dogs: central vs peripheral chemoreceptors. *J Appl Physiol* (1985) 2006;100(1):13-19.
31. Nielsen M, Smith H. Studies on the regulation of respiration in acute hypoxia; with an appendix on respiratory control during prolonged hypoxia. *Acta Physiol Scand* 1952;24(4):293-313.
32. von Euler C. The control of respiratory movement, breathlessness. Blackwell Scientific Publications; 1965.
33. Campbell EJM. The relationship of the sensation of breathlessness to the act of breathing. In: Howell BLM, Campbell EJM, editors. *Breathlessness*. Oxford: Blackwell Scientific Publications; 1965.
34. Lin RL, Gu Q, Lin YS, Lee LY. Stimulatory effect of CO<sub>2</sub> on vagal bronchopulmonary C-fiber afferents during airway inflammation. *J Appl Physiol* (1985) 2005;99(5):1704-1711.
35. Paintal AS, Anand A. Factors affecting movement of excitatory substances from pulmonary capillaries to type J receptors of anaesthetized cats. *J Physiol* 1992;449:155-168.
36. Schelegle ES. Functional morphology and physiology of slowly adapting pulmonary stretch receptors. *Anat Rec A Discov Mol Cell Evol Biol* 2003;270(1):11-16.
37. Yu J. Deflation-activated receptors, not classical inflation-activated receptors, mediate the Hering-Breuer deflation reflex. *J Appl Physiol* (1985) 2016;121(5):1041-1046.
38. Hsieh YH, Litvin DG, Zaylor AR, Nethery DE, Dick TE, Jacono FJ. Brainstem inflammation modulates the ventilatory pattern and its variability after acute lung injury in rodents. *J Physiol* 2020;598(13):2791-2811.
39. Mulder E, Pernet F, Schagatay E. A more holistic view could contribute to our understanding of “silent hypoxemia” in COVID-19 patients. *J Physiol* 2021;599(14):3627-3628.
40. Akoumianaki E, Vaporidi K, Bolaki M, Georgopoulos D. Happy or silent hypoxia in COVID-19—a misnomer born in the pandemic era. *Front Physiol* 2021;12:745634.
41. Nunn J. *Applied respiratory physiology*. London: Butterworths 1977:143-150.
42. Weil JV, Byrne-Quinn E, Sodal IE, Friesen WO, Underhill B, Filley GF, et al. Hypoxic ventilatory drive in normal man. *J Clin Invest* 1970;49(6):1061-1072.
43. Bickler PE, Feiner JR, Lipnick MS, McKleroy W. “Silent” presentation of hypoxemia and cardiorespiratory compensation in COVID-19. *Anesthesiology* 2021;134(2):262-269.
44. Ottestad W, Sovik S. COVID-19 patients with respiratory failure: what can we learn from aviation medicine? *Br J Anaesth* 2020;125(3):e280-e281.
45. Weil JV. Hypoxic drive: assessment and interpretation. *Proc R Soc Med* 1975;68(4):239.
46. Jounieaux V, Parreira VF, Aubert G, Dury M, Delguste P, Rodenstein DO. Effects of hypocapnic hyperventilation on the response to hypoxia in normal subjects receiving intermittent positive-pressure ventilation. *Chest* 2002;121(4):1141-1148.
47. Nakano T, Iwazaki M, Sasao G, Nagai A, Ebihara A, Iwamoto T, et al. Hypobaric hypoxia is not a direct dyspnoegenic factor in healthy individuals at rest. *Respir Physiol Neurobiol* 2015;218:28-31.
48. Kronenberg RS, Drage CW. Attenuation of the ventilatory and heart rate responses to hypoxia and hypercapnia with aging in normal men. *J Clin Invest* 1973;52(8):1812-1819.
49. Peterson DD, Pack AI, Silage DA, Fishman AP. Effects of aging on ventilatory and occlusion pressure responses to hypoxia and hypercapnia. *Am Rev Respir Dis* 1981;124(4):387-391.
50. Walley KR, Becker CJ, Hogan RA, Teplinsky K, Wood LD. Progressive hypoxemia limits left ventricular oxygen consumption and contractility. *Circ Res* 1988;63(5):849-859.
51. Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. *Am J Physiol* 1990;258(6 Pt 1):C967-981.
52. Kelman GR, Nunn JF, Prys-Roberts C, Greenbaum R. The influence of cardiac output on arterial oxygenation: a theoretical study. *Br J Anaesth* 1967;39(6):450-458.
53. Kumar P, Prabhakar NR. Peripheral chemoreceptors: function and plasticity of the carotid body. *Compr Physiol* 2012;2(1):141-219.
54. West JB. *Respiratory physiology: the essentials*. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2012:25, 91.
55. Javaheri S, Herrera L, Kazemi H. Ventilatory drive in acute metabolic acidosis. *J Appl Physiol Respir Environ Exerc Physiol* 1979;46(5):913-918.
56. Naifeh KH, Kamiya J. The nature of respiratory changes associated with sleep onset. *Sleep* 1981;4(1):49-59.
57. Forster HV, Pan LG, Funahashi A. Temporal pattern of arterial CO<sub>2</sub> partial pressure during exercise in humans. *J Appl Physiol* (1985) 1986;60(2):653-660.
58. Easton PA, Slykerman LJ, Anthonisen NR. Ventilatory response to sustained hypoxia in normal adults. *J Appl Physiol* (1985) 1986;61(3):906-911.
59. Burton MD, Kazemi H. Neurotransmitters in central respiratory control. *Respir Physiol* 2000;122(2-3):111-121.
60. Azad P, Stobdan T, Zhou D, Hartley I, Akbari A, Bafna V, Haddad GG. High-altitude adaptation in humans: from genomics to integrative physiology. *J Mol Med (Berl)* 2017;95(12):1269-1282.
61. Kallet RH. The year in review: mechanical ventilation during the first year of the COVID-19 pandemic. *Respir Care* 2021;66(8):1341-1362.
62. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. *Lancet* 1967;2(7511):319-323.
63. Blaisdell FW, Schlobohm RM. The respiratory distress syndrome: a review. *Surgery* 1973;74(2):251-262.
64. Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis, and principles of management. *Chest* 1971;60(3):233-239.
65. Paintal AS. Mechanism of stimulation of type J pulmonary receptors. *J Physiol* 1969;203(3):511-532.
66. Green JF, Schmidt ND, Schultz HD, Roberts AM, Coleridge HM, Coleridge JC. Pulmonary C-fibers evoke both apnea and tachypnea of pulmonary chemoreflex. *J Appl Physiol Respir Environ Exerc Physiol* 1984;57(2):562-567.
67. Kallet RH, Campbell AR, Dicker RA, Katz JA, Mackersie RC. Work of breathing during lung-protective ventilation in patients with acute lung injury and acute respiratory distress syndrome: a comparison between volume and pressure-regulated breathing modes. *Respir Care* 2005;50(12):1623-1631.
68. Kallet RH, Hemphill JC 3rd, Dicker RA, Alonso JA, Campbell AR, Mackersie RC. The spontaneous breathing pattern and work of breathing of patients with acute respiratory distress syndrome and acute lung injury. *Respir Care* 2007;52(8):989-995.
69. Spinelli E, Mauri T, Beitler JR, Pesenti A, Brodie D. Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions. *Intensive Care Med* 2020;46(4):606-618.
70. Otis AB, Fenn WO, Rahn H. Mechanics of breathing in man. *J Appl Physiol* 1950;2(11):592-607.



71. Roussos C, Fixley M, Gross D, Macklem PT. Fatigue of inspiratory muscles and their synergic behavior. *J Appl Physiol Respir Environ Exerc Physiol* 1979;46(5):897-904.
72. Banzett RB. Dynamic response characteristics of CO<sub>2</sub>-induced air hunger. *Respir Physiol* 1996;105(1-2):47-55.
73. von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, et al. Dyspnea and pain share emotion-related brain network. *Neuroimage* 2009;48(1):200-206.
74. Killian KJ. History of dyspnea. In: Mahler DA, O'Donnell DE, editors. *Dyspnea: mechanisms, measurement, and management*. Boca Raton: Taylor & Francis; 2005:1-18.
75. Campbell EJ, Howell JB. The sensation of breathlessness. *Br Med Bull* 1963;19(1):36-40.
76. Corfield DR, Fink GR, Ramsay SC, Murphy K, Harty HR, Watson JD, et al. Evidence for limbic system activation during CO<sub>2</sub>-stimulated breathing in man. *J Physiol* 1995;488(1):77-84.
77. Schwartzstein RM. Language of dyspnea. In: Mahler DA, O'Donnell DE, editors. *Dyspnea: mechanisms, measurements, and management*. Boca Raton, Florida: Taylor & Francis: 115-146.
78. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2006;3(2):180-184.
79. Rock LK, Schwartzstein RM. Mechanisms of dyspnea in chronic lung disease. *Curr Opin Support Palliat Care* 2007;1(2):102-108.
80. Schwartzstein RP. The physiology of respiratory sensations. In: Schwartzstein RP, editor. *Respiratory physiology: a clinical approach*. Philadelphia Pennsylvania: Lippincott; 2006:173.
81. von Euler C. On the role of proprioceptors in perception as execution of motor acts with special reference to breathing. In: Pengelly LR, Campbell EJM, editors. *Loaded breathing: proceedings of an international symposium on "The effects of mechanical loads in breathing."* Edinburgh and London: Churchill Livingstone; 1974:139-150.
82. Jubran A, Tobin MJ. Effect of isocapnic hypoxia on variational activity of breathing. *Am J Respir Crit Care Med* 2000;162(4):1202-1209.
83. Bickler PE, Feiner JR, Lipnick MS, Batchelder P, MacLeod DB, Severinghaus JW. Effects of acute, profound hypoxia on healthy humans: implications for safety of tests evaluating pulse oximetry or tissue oximetry performance. *Anesth Analg* 2017;124(1):146-153.
84. Moosavi SH, Golestanian E, Binks AP, Lansing RW, Brown R, Banzett RB. Hypoxic and hypercapnic drives to breathe generate equivalent levels of air hunger in humans. *J Appl Physiol* (1985) 2003;94(1):141-154.
85. Peacock AJ. ABC of oxygen: oxygen at high altitude. *BMJ* 1998;317(7165):1063-1066.
86. Ottestad W, Hansen TA, Pradhan G, Stepanek J, Hoiseth LO, Kasin JI. Acute hypoxia in a simulated high-altitude airdrop scenario due to oxygen system failure. *J Appl Physiol* (1985) 2017;123(6):1443-1450.
87. Banzett RB, Lansing RW, Evans KC, Shea SA. Stimulus-response characteristics of CO<sub>2</sub>-induced air hunger in normal subjects. *Respir Physiol* 1996;103(1):19-31.
88. Banzett RB, Lansing RW, Brown R, Topulos GP, Yager D, Steele SM, et al. "Air hunger" from increased PCO<sub>2</sub> persists after complete neuromuscular block in humans. *Respir Physiol* 1990;81(1):1-17.
89. Come S, Webster K, Younes M. Hypoxic respiratory response during acute stable hypocapnia. *Am J Respir Crit Care Med* 2003;167(9):1193-1199.
90. Bellemare F, Grassino A. Evaluation of human diaphragm fatigue. *J Appl Physiol Respir Environ Exerc Physiol* 1982;53(5):1196-1206.
91. Gallagher CG, Hof VI, Younes M. Effect of inspiratory muscle fatigue on breathing pattern. *J Appl Physiol* (1985) 1985;59(4):1152-1158.
92. Altose M, Cherniack N, Fishman AP. Respiratory sensations and dyspnea. *J Appl Physiol* (1985) 1985;58(4):1051-1054.
93. Cherniack NS, Altose MD. Mechanisms of dyspnea. *Clin Chest Med* 1987;8(2):207-214.
94. Bradley TD, Chartrand DA, Fitting JW, Killian KJ, Grassino A. The relation of inspiratory effort sensation to fatiguing patterns of the diaphragm. *Am Rev Respir Dis* 1986;134(6):1119-1124.
95. Freeman BD. Tracheostomy update: when and how. *Crit Care Clin* 2017;33(2):311-322.
96. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020;368:m1091.
97. Archer SL, Sharp WW, Weir EK. Differentiating COVID-19 pneumonia from acute respiratory distress syndrome and high-altitude pulmonary edema: therapeutic implications. *Circulation* 2020;142(2):101-104.
98. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1,000 patients with coronavirus disease 2019 in New York: retrospective case series. *BMJ* 2020;369:m1996.
99. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;395(10239):1763-1770.
100. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8(5):475-481.
101. Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. *Pharmacol Res* 2020;158:104931.
102. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020;20(4):425-434.
103. Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff BD, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. *Am J Respir Crit Care Med* 2020;201(12):1560-1564.
104. Kairaitis K, Harbut P, Hedenstierna G, Prisk GK, Farrow CE, Amis T, et al. Ventilation is not depressed in hypoxemic patients with acute COVID-19 infection. *Am J Respir Crit Care Med* 2022;205(9):1119-1120.
105. Ratnayake A, Kumarihamy P, Gunaratne S, Abeysinghe H, Perera S, Ekanayake S. Different outcomes of "Silent Hypoxia" in patients with COVID-19 pneumonia: a case series and literature review. *Case Rep Crit Care* 2021;2021:1215274.
106. Siswanto Gani M, Fauzi AR, Yuliyanti RE, Inggriani MP, Nugroho B, et al. Possible silent hypoxemia in a COVID-19 patient: a case report. *Ann Med Surg (Lond)* 2020;60:583-586.
107. Fuehner T, Renger I, Welte T, Freundt T, Gottlieb J. Silent hypoxia in COVID-19: a case series. *Respiration* 2021:1-5.
108. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al; American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med* 2012;185(4):435-452.
109. Ora J, Liguori C, Puxeddu E, Coppola A, Matino M, Pierantozzi M, et al. Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. *Neurol Sci* 2020;41(10):2671-2674.
110. Russell B. *Our knowledge of the external world as a field for scientific method in philosophy*. London: Open Court Publishing Company; 1922:105-123.
111. Guo L, Jin Z, Gan TJ, Wang E. Silent hypoxemia in patients with COVID-19 pneumonia: a review. *Med Sci Monit* 2021;27:e930776.

112. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of “happy” hypoxemia in COVID-19. *Respir Res* 2020;21(1):198.
113. Chonan T, Mulholland MB, Leitner J, Altose MD, Cherniack NS. Sensation of dyspnea during hypercapnia, exercise, and voluntary hyperventilation. *J Appl Physiol* (1985) 1990;68(5):2100-2106.
114. Kallet RH, Lipnick MS, Burns GD. The nature of recruitment and de-recruitment and its implications for management of ARDS. *Respir Care* 2021;66(3):510-530.
115. Banzett RBB, Sheridan AR, Baker KM, Lansing RW, Stevens JP. “Scared to death” dyspnea from the hospitalized patient’s perspective. *BMJ Open Respir Res* 2020;7(1).
116. Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. *Am J Respir Crit Care Med* 1996;154(1):6-17.
117. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med* 2020;46(6):1099-1102.
118. Wexler HR, Lok P. A simple formula for adjusting arterial carbon dioxide tension. *Can Anaesth Soc J* 1981;28(4):370-372.
119. Schenck EJ, Hoffman K, Goyal P, Choi J, Torres L, Rajwani K, et al. Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure. *Ann Am Thorac Soc* 2020;17(9):1158-1161.
120. Nishimura M, Miyamoto K, Suzuki A, Yamamoto H, Tsuji M, Kishi F, Kawakami Y. Ventilatory and heart rate responses to hypoxia and hypercapnia in patients with diabetes mellitus. *Thorax* 1989;44(4):251-257.
121. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10,021 patients with COVID-19 admitted to 920 German hospitals: an observational study. *Lancet Respir Med* 2020;8(9):853-862.
122. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1,591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020;323(16):1574-1581.
123. Jubran A. Pulse oximetry. *Crit Care* 2015;19:272.
124. Kelman GR. Digital computer subroutine for the conversion of oxygen tension into saturation. *J Appl Physiol* 1966;21(4):1375-1376.
125. Van de Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F, et al. Accuracy of pulse oximetry in the intensive care unit. *Intensive Care Med* 2001;27(10):1606-1613.
126. Michard F, Shelley K, L’Her E. Correction to: COVID-19: pulse oximeters in the spotlight. *J Clin Monit Comput* 2021;35(1):15.
127. Thijssen M, Janssen L, Le Noble J, Foudraïne N. Facing  $S_{pO_2}$  and  $S_{aO_2}$  discrepancies in ICU patients: is the perfusion index helpful? *J Clin Monit Comput* 2020;34(4):693-698.
128. Sjöding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial bias in pulse oximetry measurement. *N Engl J Med* 2020;383(25):2477-2478.
129. Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. *Chest* 1990;97(6):1420-1425.
130. Feiner JR, Severinghaus JW, Bickler PE. Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender. *Anesth Analg* 2007;105(6 Suppl):S18-S23.
131. Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. *Anesthesiology* 2005;102(4):715-719.
132. Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse oximeter performance, racial inequality, and the work ahead. *Respir Care* 2022;67(2):252-257.
133. Newton I. Rules of reasoning in natural philosophy (book III). 1726.
134. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020;92(6):552-555.
135. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *J Immunol* 2004;173(6):4030-4039.
136. Gattinoni L, Marini JJ, Camporota L. The respiratory drive: an overlooked tile of COVID-19 pathophysiology. *Am J Respir Crit Care Med* 2020;202(8):1079-1080.
137. Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. *J Infect Dis* 2016;213(5):712-722.
138. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 2008;82(15):7264-7275.
139. Kumar V, Singla S, Gupta N, Bharati SJ, Garg R, Pandit A, et al. The incidence of anosmia in patients with laboratory-confirmed COVID 19 infection in India: an observational study. *J Anaesthesiol Clin Pharmacol* 2021;37(1):51-56.
140. Shackman AJ, Fox AS. Contributions of the central extended amygdala to fear and anxiety. *J Neurosci* 2016;36(31):8050-8063.
141. Serrano GE, Walker JE, Arce R, Glass MJ, Vargas D, Sue LI, et al. Mapping of SARS-CoV-2 brain invasion and histopathology in COVID-19 disease. medRxiv 2021.
142. Piras IS, Huentelman MJ, Walker JE, Arce R, Glass MJ, Vargas D, et al. Olfactory bulb and amygdala gene expression changes in subjects dying with COVID-19. medRxiv 2021.
143. Fung ML. Expressions of angiotensin and cytokine receptors in the paracrine signaling of the carotid body in hypoxia and sleep apnea. *Respir Physiol Neurobiol* 2015;209:6-12.
144. Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. *Otolaryngol Head Neck Surg* 2020;163(1):12-15.